This laboratory study is part of a prospective observational cohort study. Patients were invited to a special structured nurse-based office visit at the anticoagulation clinic. All patients were followed for 1 year, during which 5 visits were planned (at start of DOAC therapy, 1 month after start DOAC, 3 months, 6 months and 12 months). Important parameters recorded during these visits were: thrombotic events and bleeding complications, side effects of medication, compliance to medication, intermittent illness and/or hospital admissions and renal function. Renal function was assessed at 4 points in time; additional blood for testing of a panel of laboratory tests was drawn. The panel of laboratory tests consisted of: APTT Actin FSL (Siemens), APTT Cephascreen (Stago), PT Innovin (Siemens), PT neoplastin (Stago), Diluted PT (DPT) Innovin (Siemens), TT Thromboclotin (Siemens), TT Thrombin (Stago), CT INTEM (ROTEM®), and CT EXTEM (ROTEM®, Werfen). Diluted TT Hemoclot (Biophen) was set as gold standard for the detection of dabigatran and anti Xa activity DiXal (Biophen) for the detection of rivaroxaban. For this paper clinical details are not presented because the blood samples were purely used for laboratory validation.
Aptt actin fsl
Manufactured by Siemens
Sourced in Germany
APTT Actin FSL is a laboratory equipment product from Siemens. It is used to perform the activated partial thromboplastin time (APTT) test, which is a common coagulation assay. The APTT Actin FSL measures the time it takes for a patient's blood to clot, providing information about the function of the intrinsic and common coagulation pathways.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using aptt actin fsl
1
Validating Anticoagulant Lab Assays
2
Lupus Anticoagulant Diagnostic Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Study of LA was performed in patients not receiving oral anticoagulants or heparin. Samples were collected with sodium citrate as anticoagulant and then, subjected to double centrifugation in order to obtain platelet-poor plasma. Protocol for LA study followed the criteria of the International Society on Thrombosis and Haemostasis 2009. As screening tests, we used aPTT Actin FSL (Siemens, Munich, Germany), PTT-LA (Stago, Asnie`res-sur-Seine, France), dilute Russell's viper venom time dRVVT (Stago, Asnie`res-sur-Seine, France) and mixtures with normal plasma for the determination of correction or no correction of altered tests. In the case of positive screening tests, we performed confirmatory tests using reagents with high concentrations of phospholipids as the test of neutralization with hexagonal phospholipids Staclot-LA (Stago, Asnie`ressur-Seine, France).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!